WaveMan
WaveMan · Company
XRAY · Dentsply Sirona Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

XRAY Dentsply Sirona (XRAY) Insider Trading, Ownership & Congress Trades

Medical Devices · Dental equipment & supplies · CIK 0000818479
Quote by TradingView
Cluster · 6 insiders
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
210
13F, latest reported quarter

What the filings say about XRAY

Insiders, 180 days
+$617.3K net bought
6 buyers
Congress, 1 year
No trades
Last one: sale, 2025-01-08

Dentsply Sirona insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, DENTSPLY SIRONA Inc. insiders bought a net $617.3K of stock across 34 Form 4 purchases and sales, with 6 insiders buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
HOSEIN CLYDE
Director
BUY
2026-06-16 SECtraded 2026-06-15
6,500
$64.9K
-8.1%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 9.2% of the 70,575 shares held after it.
  • 5 other insiders bought within 30 days.
  • 210 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director HOSEIN CLYDE bought about $64.9K of XRAY on Jun 15, 2026; 5 other insiders bought within 30 days and 210 funds added in the latest 13F quarter.
Gladden Brian T
Director
BUY
2026-06-15 SEC
9,985.02
$100.0K
-11.8%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 16.1% of the 61,848 shares held after it.
  • 5 other insiders bought within 30 days.
  • 210 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Gladden Brian T bought about $100.0K of XRAY on Jun 15, 2026; 5 other insiders bought within 30 days and 210 funds added in the latest 13F quarter.
MAZELSKY JONATHAN JAY
Director
BUY
2026-06-18 SECtraded 2026-06-12
10,000
$101.4K
-9.2%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 16.2% of the 61,668 shares held after it.
  • 5 other insiders bought within 30 days.
  • 210 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director MAZELSKY JONATHAN JAY bought about $101.4K of XRAY on Jun 12, 2026; 5 other insiders bought within 30 days and 210 funds added in the latest 13F quarter.
MCKEON BRIAN P
Director
BUY
2026-06-15 SECtraded 2026-06-12
10,000
$101.2K
-11.8%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 100.0% of the 10,000 shares held after it.
  • 5 other insiders bought within 30 days.
  • 210 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director MCKEON BRIAN P bought about $101.2K of XRAY on Jun 12, 2026; 5 other insiders bought within 30 days and 210 funds added in the latest 13F quarter.
HOLDEN BETSY D
Director
BUY
2026-06-15 SECtraded 2026-06-11
10,086
$99.6K
-11.8%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 11.5% of the 87,528 shares held after it.
  • 5 other insiders bought within 30 days.
  • 210 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director HOLDEN BETSY D bought about $99.6K of XRAY on Jun 11, 2026; 5 other insiders bought within 30 days and 210 funds added in the latest 13F quarter.
34 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 29 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$617.3K over 180 days
more than 89% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
210 funds bought in last quarter
more than 84% of Medical Devices
Revenue
-3.0% year over year
below 80% of Medical Devices
Margin
-16.3% net margin
more than 51% of Medical Devices
Buybacks
$12.0M repurchased, FY to 2026-06-30
below 59% of Medical Devices
Short interest
13.6% of the float short (float per yahoo 2026-10-26) · 4.5 days to cover · settled 2026-09-30
more than 93% of Medical Devices
The situation: each line is one rule over one dataset
6 insiders independently bought a net $617.3K while the stock fell 23% over six months, with no planned sales queued.
What changed in the last 30 days
Oct 27Insider buying stopped: no purchases in 90 days after 6 in the prior 90
Why it matters
The absence is the signal: 6 purchases in one 90-day window and none in the next is a change of behaviour, not a filing.

Watch XRAY

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-28.2%12M
-34%-18%-2%+14%2025-102025-122026-022026-042026-062026-082026-10 2025-12-08 · LUCIER GREGORY T sold $915.7K2026-03-02 · LUCIER GREGORY T bought $392.7K2026-03-03 · LUCIER GREGORY T bought $314.9K2026-03-09 · LUCIER GREGORY T bought $186.8K2026-06-11 · Barber Michael J bought $150.1K2026-06-12 · MAZELSKY JONATHAN JAY bought $101.4K2026-06-12 · MCKEON BRIAN P bought $101.2K2026-06-15 · Gladden Brian T bought $100.0K2025-11-24 · VARON LESLIE F bought $100.0K2026-06-11 · HOLDEN BETSY D bought $99.6K2026-03-03 · Forbes James D bought $67.3K2026-06-15 · HOSEIN CLYDE bought $64.9K2026-03-09 · Forbes James D bought $62.4K
Insider buyInsider sell
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns XRAY: institutional holders (13F)

13F holdings, latest reported quarter
BlackRock, Inc.
26,711,079 sh
$283.4M
FULLER & THALER ASSET MANAGEMENT, INC.
12,697,269 sh
$134.7M
VANGUARD PORTFOLIO MANAGEMENT LLC
11,779,851 sh
$125.0M
AQR CAPITAL MANAGEMENT LLC
10,458,771 sh
$110.2M
STATE STREET CORP
9,285,298 sh
$98.5M

Congress trades in XRAY

STOCK Act disclosures, US House only, filed up to 45 days after the trade
Gilbert Cisneros
Sold 2025-01-08 · disclosed 34 days later
$1,001 - $15,000
Gilbert Cisneros
Sold 2025-01-07 · disclosed 35 days later
$1,001 - $15,000
All stocks members of Congress are buying · Every member's trades

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

XRAY planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

XRAY mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Lazard Equity Franchise Portfolio
$1.8M position · as of 2026-06-30
4.9%
The 3D Printing ETF
$2.8M position · as of 2026-07-31
4.7%
Paradigm Micro-Cap Fund
$5.3M position · as of 2026-06-30
2.9%
Ariel Fund
$82.7M position · as of 2026-06-30
2.9%
Paradigm Value Fund
$1.5M position · as of 2026-06-30
2.7%
Invenomic Fund
$21.7M position · as of 2026-07-31
2.5%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Executive pay vs shareholder return · Mr.Campion
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2024
$8.7M
-$1.6M
$2.8M
-61%
+29%
2023
$8.5M
$9.3M
$3.7M
-29%
+26%
2021
$9.3M
$20.1M
$2.4M
+7%
+26%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
6 insiders reported buying shares.
The record shows a net $617.3K bought by insiders over 180 days, 210 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
PENBLFSMTDSIBNWRBYISRGTXGDXCMEWTMDXOMIRMD

XRAY financials

Revenue growth
-3.0%
XBRL, annual
Net margin
-16.3%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$3.6B
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-15.0%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
$143.0M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
1.65x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Cash flow to debt
0.14x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Return on equity
-33.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-9.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-6.9%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$3.8B
market value at close 2026-10-26 on 2026-07-24 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
FCF yield
+7.8%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$3.7B$3.8B$4.0B$3.9B
Gross profit$1.8B$2.0B$2.1B$2.1B
Operating income-$422.0M-$879.0M-$85.0M-$937.0M
Net income-$598.0M-$910.0M-$132.0M-$950.0M
EPS (diluted)-3.00-4.48-0.62-4.41
Operating cash flow$235.0M$461.0M$377.0M$517.0M
Cash$326.0M$272.0M$334.0M$365.0M
Long-term debt$2.0B$1.6B$1.8B$1.8B
Buybacks$0$250.0M$300.0M$150.0M
Dividends paid$128.0M$126.0M$116.0M$104.0M
SEC XBRL, fiscal years, as known on 2026-10-27

XRAY Stock Sonar score 6/7 axes

Find similar shapesCompare

XRAY ranks highest on insider conviction (94th percentile) and institutional and government (59th), and lowest on growth (20th), among Medical Devices peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
54
Inputs
  • Return on equity-33.0% · 45 pct, sector of 183
  • Return on assets-9.7% · 56 pct, sector of 214
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-6.9% · 59 pct, sector of 188
Financial health
40
Inputs
  • Debt to equity1.65x · 13 pct, sector of 159
  • Cash flow to debt0.14x · 66 pct, sector of 150
Growth
20
Inputs
  • Revenue growth, YoY-3.0% · 20 pct, sector of 219
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
94
Inputs
  • Net Form 4 buying (codes P and S), 180d$617K · 88 pct, sector of 140
  • Insider buyers, 180d6 · 99 pct, sector of 142
Institutional and government
59
Inputs
  • Funds adding, latest quarter210 · 84 pct, sector of 191
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quarters$140K · 35 pct, sector of 50
Risk and compliance
44
Inputs
  • Short interest, % of float+13.6% · 11 pct, sector of 240
  • Recalls per $1B revenue, 3y0.00 per $1B · 100 pct, sector of 116
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+18.2% · 21 pct, sector of 198
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

XRAY filings, in plain words

Are Dentsply Sirona insiders buying or selling XRAY?

In the 180 days to 2026-10-27, Dentsply Sirona insiders were net buyers, a net $617.3K across purchases and sales reported on Form 4, by 6 buyers.

Have members of Congress traded XRAY?

Yes, but not in the year to 2026-10-27; the latest on record is a sale by Gilbert Cisneros dated 2025-01-08.

Read the full summary

In the 180 days to 2026-10-27, Dentsply Sirona insiders were net buyers of XRAY, a net $617.3K across purchases and sales reported on Form 4 by 6 buyers. 6 insiders reported purchases in that window. Members of Congress have disclosed trades in XRAY, none in the last year; the latest on record is a sale by Gilbert Cisneros dated 2025-01-08. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies